List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2368452/publications.pdf Version: 2024-02-01



FMILY RETH DEVINE

#	Article	IF	CITATIONS
1	Patient-centred outcomes of imaging tests: recommendations for patients, clinicians and researchers. BMJ Quality and Safety, 2023, 32, 536-545.	3.7	4
2	Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Advances, 2023, 7, 365-374.	5.2	26
3	Health State Utilities for Sickle Cell Disease: A Catalog Prepared From aÂSystematic Review. Value in Health, 2022, 25, 276-287.	0.3	3
4	Clinical Outcomes of Different Warfarin Self-Care Strategies: A Systematic Review and Network Meta-Analysis. Thrombosis and Haemostasis, 2022, 122, 492-505.	3.4	9
5	Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment. Value in Health, 2022, 25, 443-450.	0.3	4
6	Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC) Journal of Clinical Oncology, 2022, 40, 570-570.	1.6	1
7	Prevalence and prediction of medical distrust in aÂdiverse medical genomic research sample. Genetics in Medicine, 2022, 24, 1459-1467.	2.4	7
8	Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis. Pharmacogenomics Journal, 2022, 22, 188-197.	2.0	4
9	Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis. PharmacoEconomics - Open, 2022, 6, 469-481.	1.8	14
10	Use of geriatric assessment in cancer clinical trials: A systematic review. Journal of Geriatric Oncology, 2022, 13, 907-913.	1.0	8
11	Assessing the Value of Remote Patient Monitoring Solutions in Addressing Challenges in Patient Care. Value in Health, 2022, 25, 887-889.	0.3	2
12	Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease. PLoS ONE, 2022, 17, e0267448.	2.5	4
13	Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease. Quality of Life Research, 2022, 31, 2729-2738.	3.1	2
14	Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1225-1234.	3.6	8
15	Metaâ€∎nalyzing count events over varying durations using the piecewise Poisson model: The case for poststroke seizures. Research Synthesis Methods, 2021, 12, 347-356.	8.7	0
16	Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses. Medical Decision Making, 2021, 41, 366-372.	2.4	3
17	Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care. Contemporary Clinical Trials, 2021, 101, 106257.	1.8	5
18	Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study. Clinical Ophthalmology, 2021, Volume 15, 453-460.	1.8	2

#	Article	IF	CITATIONS
19	Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 223-239.	0.9	8
20	Healthcare Resource Utilization and Costs in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Clinical Ophthalmology, 2021, Volume 15, 2643-2651.	1.8	0
21	The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature. Pharmacoeconomics, 2021, 39, 1225-1241.	3.3	7
22	Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 95-104.	0.9	1
23	Use of real-world evidence in economic assessments of pharmaceuticals in the United States. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 5-14.	0.9	11
24	Comparative efficacy of strategies to support self-management in patients with asthma: a systematic review and network meta-analysis. Journal of Allergy and Clinical Immunology: in Practice, 2021, , .	3.8	8
25	Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks. Headache, 2021, , .	3.9	2
26	Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. Research in Social and Administrative Pharmacy, 2020, 16, 1033-1040.	3.0	13
27	The use of real-world evidence in ICER's scoping process and clinical evidence assessments. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1590-1595.	0.9	1
28	Letter to the editor for a published article titled "The effect of online versus hospital warfarin management on patient outcomes: a systematic review and meta-analysis― International Journal of Clinical Pharmacy, 2020, 42, 1-2.	2.1	4
29	Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 325-331.	0.9	1
30	Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration. Health Services Research, 2019, 54, 1055-1064.	2.0	28
31	Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention. Value in Health, 2019, 22, 1231-1239.	0.3	10
32	A Secondary Analysis to Identify Patient-Centered Outcomes in the ACR'sÂAppropriateness Criteria. Journal of the American College of Radiology, 2019, 16, 1645-1655.	1.8	4
33	Psoriasis treatment patterns: a retrospective claims study. Current Medical Research and Opinion, 2019, 35, 1727-1733.	1.9	12
34	Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR). Quality of Life Research, 2018, 27, 2581-2591.	3.1	25
35	The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care Utilization Among Patients Treated With Polymyxins for Severe Gram-Negative Infections. Open Forum Infectious Diseases, 2018, 5, ofy191.	0.9	9
36	Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation. Journal of Comparative Effectiveness Research, 2018, 7, 167-175.	1.4	1

#	Article	IF	CITATIONS
37	Empowering genomic medicine by establishing critical sequencing result data flows: the eMERGE example. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1375-1381.	4.4	21
38	Automating Electronic Clinical Data Capture for Quality Improvement and Research: The CERTAIN Validation Project of Real World Evidence. EGEMS (Washington, DC), 2018, 6, 8.	2.0	9
39	Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis. Journal of Virus Eradication, 2018, 4, 118-122.	0.5	7
40	Using the Analytic Hierarchy Process for Prioritizing Imaging Tests in Diagnosis of Suspected Appendicitis. Academic Radiology, 2017, 24, 530-537.	2.5	15
41	Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs, 2017, 31, 421-432.	5.9	61
42	Toward a Framework for Benefit-Risk Assessment in Diagnostic Imaging. Academic Radiology, 2017, 24, 538-549.	2.5	5
43	The Association Between Unhealthy Alcohol Use and Acute Care Expenditures in the 30ÂDays Following Hospital Discharge Among Older Veterans Affairs Patients with a Medical Condition. Journal of Behavioral Health Services and Research, 2017, 44, 602-624.	1.4	6
44	The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review. PharmacoEconomics - Open, 2017, 1, 1-12.	1.8	20
45	Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis. BMC Gastroenterology, 2017, 17, 52.	2.0	43
46	Health Information Exchange Use (1990-2015): A Systematic Review. EGEMS (Washington, DC), 2017, 5, 27.	2.0	29
47	Preparing Electronic Clinical Data for Quality Improvement and Comparative Effectiveness Research: The SCOAP CERTAIN Automation and Validation Project. EGEMS (Washington, DC), 2017, 1, 16.	2.0	19
48	Achieving and Sustaining Automated Health Data Linkages for Learning Systems: Barriers and Solutions. EGEMS (Washington, DC), 2017, 2, 3.	2.0	10
49	Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis. Gastroenterology Research and Practice, 2016, 2016, 1-18.	1.5	19
50	Preference weights for the spectrum of alcohol use in the U.S. Population. Drug and Alcohol Dependence, 2016, 161, 206-213.	3.2	8
51	Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. International Journal of Medical Informatics, 2016, 86, 117-125.	3.3	16
52	The Value of Computerized Provider Order Entry: Is It Time for the Debate to Be Over?. Joint Commission Journal on Quality and Patient Safety, 2015, 41, 339-340.	0.7	0
53	Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians. Journal of Biomedical Informatics, 2015, 55, 249-259.	4.3	27
54	Outcomes From Health Information Exchange: Systematic Review and Future Research Needs. JMIR Medical Informatics, 2015, 3, e39.	2.6	102

#	Article	IF	CITATIONS
55	Health Information Exchange. , 2015, , 1-465.		15
56	Cost-Effectiveness of a Computerized Provider Order Entry System in Improving Medication Safety Ambulatory Care. Value in Health, 2014, 17, 340-349.	0.3	30
57	Applying Quantitative Benefit–Risk Analysis to Aid Regulatory Decision Making in Diagnostic Imaging. Academic Radiology, 2014, 21, 1138-1143.	2.5	13
58	Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: A mixed methods approach. International Journal of Medical Informatics, 2014, 83, 473-483.	3.3	71
59	A model for incorporating patient and stakeholder voices in a learning health care network: Washington State's Comparative Effectiveness Research Translation Network. Journal of Clinical Epidemiology, 2013, 66, S122-S129.	5.0	40
60	Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions. Journal of the American Medical Informatics Association: JAMIA, 2012, 19, 840-850.	4.4	4
61	Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach. Pharmacotherapy, 2011, 31, 39-51.	2.6	56
62	Prescriber and staff perceptions of an electronic prescribing system in primary care: a qualitative assessment. BMC Medical Informatics and Decision Making, 2010, 10, 72.	3.0	27
63	Postoperative Acquired Coagulopathy: A Pilot Study to Determine the Impact on Clinical and Economic Outcomes. Pharmacotherapy, 2010, 30, 994-1003.	2.6	7
64	Electronic Prescribing at the Point of Care: A Time–Motion Study in the Primary Care Setting. Health Services Research, 2010, 45, 152-171.	2.0	52
65	The impact of computerized provider order entry on medication errors in a multispecialty group practice. Journal of the American Medical Informatics Association: JAMIA, 2010, 17, 78-84.	4.4	131
66	Assessing attitudes toward electronic prescribing adoption in primary care: a survey of prescribers and staff. Journal of Innovation in Health Informatics, 2010, 18, 177-187.	0.9	9
67	The art of obtaining grants. American Journal of Health-System Pharmacy, 2009, 66, 580-587.	1.0	17
68	Characterization of prescribing errors in an internal medicine clinic. American Journal of Health-System Pharmacy, 2007, 64, 1062-1070.	1.0	45
69	A Systematic Review of Patient-Reported Outcome Instruments Measuring Sleep Dysfunction in Adults. Pharmacoeconomics, 2005, 23, 889-912.	3.3	88
70	Health-related quality of life assessment in chronic kidney disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 89-100.	1.4	12
71	Cost-Benefit Analysis of a Clinical Pharmacist's Presence on a Post-Liver Transplant Service (Confessions of Some Accidental Hermeneuticians). Hospital Pharmacy, 2000, 35, 1197-1202.	1.0	1
72	Evaluating the Feasibility of Performing Pharmacogenetic Guidedâ€Medication Therapy Management in a Retirement Community: A Prospective, Single arm Study. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	0